65,437 trials
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) — 3.7…
NASH
Primary: Part 1: Number of Participants With Treatment-emergent Adverse Event (TEAEs) — 6; 4; 7; 7 Participants
Asthma
Primary: Time to First Severe Exacerbation — 43.75; 49.43 Days — p=0.758
Opioid-use Disorder
Primary: Change in Negative Affect — 1.67; 1.25; 3.60 scores on a scale
Psychosis · First Episode Psychosis · Clinical High Risk for Psychosis
Primary: Duration of Untreated Psychosis
Anxiety
Primary: mYPAS Anxiety Score, Patients With Scores of 30 or More Indicated "Anxiety" — 20; 22 Participants — p=0.44
CNS Lymphoma · CNS Brain Cancer · Non-Hodgkin's Lymphoma
Primary: Number of Participants Evaluated for Toxicity — 33 Participants
Progressive Supranuclear Palsy · Dementia With Lewy Bodies · Multiple System Atrophy
Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59
Nonsene Mutation Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 5 Participants
Multiple Myeloma
Primary: Phase 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Bariatric Surgery Candidate
Primary: Weight in Kg — 111.4; 116.4; 89.7; 93.5 Kg
Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma · Stage II Oropharyngeal Squamous Cell Carcinoma · Stage III Hypopharyngeal Squamous Cell Carcinoma
Primary: Pathologic Complete Response Rate — 45.5 percentage of complete response
Opioid Use · Opioid-use Disorder
Primary: Hospital Length of Stay — 232.1; 215.0 Hours
Smoking · Smoking Cessation
Primary: Intervention (App) Utilization — 4.9; 8.2 User sessions — p=0.219
Injury Leg · Injury, Knee · Injury;Sports
Primary: Landing Error Scoring System (LESS) Score — 6; 5.8; 5.2 errors